External validation of the VTE-PREDICT score for predicting recurrence and bleeding in venous thromboembolism: results from the Registro Informatizado Enfermedad TromboEmbolica Registry
Por:
Hoberstorfer, T, Nopp, S, Steiner, D, Hernandez-Blasco, L, Jou, I, Lopez-Núñez, JJ, Fidalgo, A, Lopez-Miguel, P, Monreal, M and Ay, C
Publicada:
1 dic 2025
Ahead of Print:
1 nov 2025
Resumen:
Background: The VTE-PREDICT score predicts venous thromboembolism (VTE) recurrence and clinically relevant bleeding (CRB; major and clinically relevant nonmajor bleeding) after acute VTE.
Objectives: We aimed to externally validate the VTE-PREDICT score in the Registro Informatizado Enfermedad TromboEmbolica, a prospective registry of patients with VTE.
Methods: Exclusion criteria included enrollment before 2012, active cancer, and anticoagulation other than direct oral anticoagulants, vitamin K antagonists, or low-molecular-weight heparin. VTE recurrence and CRB risks were calculated using VTE-PREDICT for a prediction period of 3 months after the index VTE until the following 1 to 5 years. Predicted risks were then compared with observed risks. C-statistics and calibration plots were assessed.
Results: In total, 17 850 patients (50.3% women) were included in the final analysis, of whom 64.3% had pulmonary embolism. The median age was 67 years (IQR, 52-78). Regarding long-term anticoagulation, 21.8% of patients were treated with a direct oral anticoagulant, 39.9% with a vitamin K antagonist, and 4.8% with low-molecular-weight heparin, whereas 33.6% received no anticoagulant treatment. Cumulative incidences of VTE recurrence and CRB at 1 year were 3.7% (95% CI, 3.4%-4.0%) and 2.6% (95% CI, 2.4%-2.9%), respectively. The c-statistics of VTE-PREDICT for 1 to 5 years varied between 0.70 (95% CI, 0.67-0.72) and 0.73 (95% CI, 0.69-0.76) for VTE recurrence and between 0.65 (95% CI, 0.63-0.67) and 0.67 (95% CI, 0.64-0.70) for CRB. Calibration analysis revealed underestimation of VTE recurrence and overestimation of CRB risk.
Conclusion: VTE-PREDICT showed good discrimination for VTE recurrence and moderate discrimination for CRB, but underestimated the risk of VTE recurrence in high-risk patients.
Filiaciones:
Hoberstorfer, T:
Med Univ Vienna, Dept Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
Nopp, S:
Med Univ Vienna, Dept Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
Steiner, D:
Med Univ Vienna, Dept Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
Hernandez-Blasco, L:
Miguel Hernandez Univ, Dr Balmis Univ Gen Hosp, Alicante Inst Hlth & Biomed Res ISABIAL, Pneumol Dept Clin Med, Alicante, Spain
Jou, I:
Hosp Univ Girona Dr Josep Trueta, Dept Internal Med, Girona, Spain
:
Hosp Germans Trias i Pujol, Dept Internal Med, Badalona, Barcelona, Spain
Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
Inst Recerca Germans Trias i Pujol, Internal Med Dept, Badalona, Barcelona, Spain
Fidalgo, A:
Hosp Univ Salamanca, Dept Internal Med, Salamanca, Spain
Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain
Lopez-Miguel, P:
Hosp Gen Univ Albacete, Dept Pneumonol, Albacete, Spain
Monreal, M:
Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain
Univ Catolica San Antonio Murcia, Fac Hlth Sci, Murcia, Spain
Ay, C:
Med Univ Vienna, Dept Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
Green Submitted, hybrid
|